GLP-1s and Nutrition: Why Eating Less is Not the Same as Eating Well
GLP-1-based therapies are changing the landscape of obesity and metabolic health care. These medicines can support substantial weight loss and improvements in cardiometabolic health, and they are becoming an increasingly prominent part of clinical practice.
But as PAN International’s new white paper, Beyond the Prescription: Why Nutrition Support is Essential Across the GLP-1 Treatment Journey, makes clear, medication is not the whole story.
As appetite, food intake and nutritional needs change during treatment, patients need credible, practical nutrition support to help protect dietary quality, nutritional adequacy, muscle and bone health, treatment tolerance and long-term wellbeing. PAN’s position is not to challenge the existence, prescription or promise of GLP-1-based therapies. It is to make the missing nutritional support layer visible.
The core message is simple: eating less is not the same as eating well.
Why nutrition support matters during GLP-1 care
GLP-1-based therapies can substantially reduce body weight and improve cardiometabolic health. However, reduced food intake and substantial weight loss can also increase nutritional and clinical risks, including inadequate nutrient intake, loss of muscle mass and gastrointestinal complications.
This is why nutrition support should not only be introduced when concerns or symptoms emerge. It should be integrated throughout the treatment journey, helping patients maintain nutritional adequacy, protect dietary quality, support treatment tolerance and identify nutritional risk early.
Weight loss is not the only measure of health
GLP-1 treatment is often discussed through the lens of weight loss, but health outcomes depend on more than the number on the scale.
Dietary quality, nutritional adequacy, muscle and bone health, physical function, symptom management and long-term health behaviours also matter. Nutrition support helps shift the conversation from “How much weight was lost?” to “How well is the patient being supported?”
This is especially important because appetite suppression and reduced food intake can make it harder for some patients to meet their nutritional needs. PAN’s white paper highlights the importance of early assessment and monitoring, with more intensive support for people at greater nutritional or clinical risk.
There is no single “GLP-1 diet”
Current evidence does not support one universal GLP-1-specific diet. Instead, nutrition support should build on established principles of healthy, nutrient-dense dietary patterns, while being adapted to each patient’s clinical needs, cultural context, food access and treatment stage.
For PAN, this means avoiding rigid diet rules, commercial product claims or one-size-fits-all messaging. The focus should be on practical, evidence-informed guidance that supports dietary quality, diversity, adequate protein, fibre, hydration, physical activity and referral where needed.
Read the full white paper on PANCO
PAN International’s white paper provides a more detailed review of the evidence, current guidance, country-level perspectives and practical priorities for integrating nutrition support into GLP-1 care.
The full paper is available for free on PANCO, PAN’s online learning and community platform.
Access the full white paper here.